Previous 10 | Next 10 |
WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has completed the...
WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will par...
TScan Therapeutics (NASDAQ:TCRX): Q3 GAAP EPS of -$0.80 beats by $0.16. Revenue of $2.41M beats by $0.05M. Cash and cash equivalents totaling $182.3M Press Release For further details see: TScan Therapeutics EPS beats by $0.16, beats on revenue
IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid Tumor Program Targeting HPV16; TCR Advancing into IND-Enabling Activities with IND Submission Planned for Second Half of 2022 ...
WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that two abstracts relate...
Point Roberts, WA and Delta, BC - October 22, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining and Cannabis. Today's stocks have been added to our lists of free st...
Gainers: Jasper Therapeutics (NASDAQ:JSPR) +22%, 23andMe (NASDAQ:ME) +21%, DBV Technologies (NASDAQ:DBVT) +10%, ABVC BioPharma (NASDAQ:ABVC) +10%, Sonoma Pharmaceuticals (NASDAQ:SNOA) +8% Losers: Grove (NASDAQ:GRVI) -12%, Myomo (NYSE:MYO) -11%...
WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Heathe...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, Pr...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...